Pfizer-BioNTech COVID-19 Vaccine Elicits Strong Immune Response in Kids Under 5 After Third Dose
The trial included 1678 children who received a third dose of the 3µg formulation at least 2 months after the second dose of a 2-dose series at a time when Omicron was the predominant variant.